Press Releases

NEWS RELEASE

August 3, 2011

IMBiotechnologies announces issuance of patents in the USA and Australia

EDMONTON, ALBERTA - IMBiotechnologies Ltd. ("IMB"), a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced the issuance of patents in the USA and Australia protecting its Lead Product, Occlusin® 500 Artificial Embolization Device (OCL 500) and its pipeline products.

US patent 7,947,282 provides issued claims that protect the use of IMB’s lead and pipeline products in combination with a broad range of additional therapies to treat numerous diseases and conditions.  Australia patent 2002334266 provides issued claims that protect compositions and methods of using IMB’s lead and pipeline products.

IMB has patents issued in the USA, Europe and other territories around the world.  IMB continues to vigorously pursue additional patent protection in various jurisdictions worldwide.

About IMBiotechnologies Lead Product - OCL 500

OCL 500 is the first biodegradable embolization device cleared by the United States Food and Drug Administration (FDA) for the treatment of unresectable/inoperable hypervascularized tumours.  A first-in-class embolic agent representing a paradigm shift in treatment compared to currently-marketed embolic agents, OCL 500 is a microspherical agent that uses an active clotting mechanism to rapidly form a tight, efficient, site-specific and platelet-rich clot that fully cuts off the blood supply to tumours.  The OCL microspheres then completely biodegrade, allowing treated blood vessels to re-open, enabling multiple additional embolization treatments of unresectable hypervascularized tumours such as those associated with liver and kidney cancer.  A key benefit of multiple additional embolization treatments may be increased survival while patients with liver and kidney cancer wait to receive an organ transplant.

About IMB

IMB is a privately held Canadian biotechnology company focused on developing medical device products for use in the area of embolotherapy.  Lead product, OCL 500 microspheres for the treatment of unresectable/inoperable hypervascularized tumours has received marketing clearance from the FDA.  Other products in development include rapidly-dissolving, drug-eluting and/or radio-labelled microspheres for treatment of benign and malignant tumours as well as Occlusin®-based coils and stents for use in the treatment of aneurysms and varicoceles.

About Embolotherapy

Embolotherapy works by cutting off blood flow to benign and malignant hypervascular tumours.  The procedure is performed by injecting agents through a catheter into the blood vessels that feed the target tumour.  By selectively blocking blood supply, the deprived tumour is either destroyed or devitalized, resulting in therapeutic benefit.  Hypervascular tumours are characterized by having an excessive number of blood vessels. Embolotherapy is a minimally invasive treatment for hypervascular tumours such as liver and kidney cancers as well as uterine fibroids.  According to the National Cancer Institute, there are approximately 25,000 Americans with liver and intrahepatic bile duct cancer, and approximately 266,000 with kidney and renal pelvic cancer. Across the U.S., approximately 300,000 hysterectomies and 70,000 myomectomies are performed annually to treat uterine fibroids.

This press release may contain forward-looking statements and predictions.  These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements.  The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company may ultimately prove to be incorrect.  The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

FOR FURTHER INFORMATION PLEASE CONTACT:

IMBiotechnologies Ltd.

IMBiotechnologies Ltd.

Michael Stewart

Jean-Paul Laurin

President & CEO

Vice President, Business Development

(780) 945-6609

(905) 220-9933

mstewart@tbwifi.ca

jp.imbiotechnologies@bell.net

 

 

NEWS RELEASE

August 3, 2011

IMBiotechnologies announces Cardiovascular and Interventional Radiology Journal publication of preclinical study of Occlusin® 500 Artificial Embolization Device vs Embosphere® Microspheres

 

EDMONTON, ALBERTA - IMBiotechnologies Ltd. ("IMB"), a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that a manuscript for a preclinical study of lead product Occlusin® 500 Artificial Embolization Device (OCL 500) has been accepted for publication in an upcoming issue of Cardiovascular and Interventional Radiology, the official journal of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), the Japanese Society of Interventional Radiology and the British Society of Interventional Radiology. The publication is available online in advance of print publication, at http://www.springer.com/medicine/radiology/journal/270.

The study, which compared OCL 503 (150 µm – 212 µm) to Embosphere® Microspheres (300 µm – 500 µm) in unilateral Uterine Artery Embolization (UAE) performed on 32 adult  female sheep, demonstrated that 1) OCL is as effective as Embosphere® Microspheres at embolizing ovine uterine arteries, and 2) OCL completely resorbs with time, allowing recanalization of the treated arteries.  In contrast Embosphere® Microsphere treated arteries remained completely occluded after one year.  Further, OCL was found in the untreated contralateral uterine artery in one animal with no other evidence of non target embolization, while in the Embosphere®-treated group, all vessels remained occluded and Embosphere® Microspheres were found in the contralateral uterine artery in 6 of 15 examined vessels, and in 10 vaginal, 2 ovarian, and 1 vesical artery. No device-related issues or adverse events were seen in either group.

About OCL 500

OCL 500 is the first biodegradable embolization device cleared by the United States Food and Drug Administration (FDA) for the treatment of unresectable/inoperable hypervascularized tumours.  A first-in-class embolic agent representing a paradigm shift in treatment compared to currently-marketed embolic agents, OCL 500 is a microspherical agent that uses an active clotting mechanism to rapidly form a tight, efficient, site-specific and platelet-rich clot that fully cuts off the blood supply to tumours.  The OCL microspheres then completely biodegrade, allowing treated blood vessels to re-open, enabling multiple additional embolization treatments of unresectable hypervascularized tumours such as those associated with liver and kidney cancer.  A key benefit of multiple additional embolization treatments may be increased survival while patients with liver and kidney cancer wait to receive an organ transplant.

About IMB

IMB is a privately held Canadian biotechnology company focused on developing medical device products for use in the area of embolotherapy.  Lead product, OCL 500 microspheres for the treatment of unresectable/inoperable hypervascularized tumours has received marketing clearance from the FDA.  Other products in development include rapidly-dissolving, drug-eluting and/or radio-labelled microspheres for treatment of benign and malignant tumours as well as Occlusin®-based coils and stents for use in the treatment of aneurysms and varicoceles.

About Embolotherapy

Embolotherapy works by cutting off blood flow to benign and malignant hypervascular tumours.  The procedure is performed by injecting agents through a catheter into the blood vessels that feed the target tumour.  By selectively blocking blood supply, the deprived tumour is either destroyed or devitalized, resulting in therapeutic benefit.  Hypervascular tumours are characterized by having an excessive number of blood vessels. Embolotherapy is a minimally invasive treatment for hypervascular tumours such as liver and kidney cancers as well as uterine fibroids.  According to the National Cancer Institute, there are approximately 25,000 Americans with liver and intrahepatic bile duct cancer, and approximately 266,000 with kidney and renal pelvic cancer. Across the U.S., approximately 300,000 hysterectomies and 70,000 myomectomies are performed annually to treat uterine fibroids.

This press release may contain forward-looking statements and predictions.  These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements.  The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company may ultimately prove to be incorrect.  The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

FOR FURTHER INFORMATION PLEASE CONTACT:

IMBiotechnologies Ltd.

IMBiotechnologies Ltd.

Michael Stewart

Jean-Paul Laurin

President & CEO

Vice President, Business Development

(780) 945-6609

(905) 220-9933

mstewart@tbwifi.ca

jp.imbiotechnologies@bell.net

NEWS RELEASE

May 11, 2010

IMBiotechnologies Receives FDA Clearance to Market Occlusin® 500 Biodegradable Microspheres in the U.S.

EDMONTON, ALBERTA - IMBiotechnologies Ltd. ("IMBio"), a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received regulatory concurrence from the United States Food and Drug Administration (FDA) to market its lead product, Occlusin® 500 Artificial Embolization Device (OCL 500) in the U.S. for the treatment of unresectable/inoperable hypervascularized tumours. IMBio filed the 510(k) submission in December 2009. OCL 500 is the first biodegradable embolization device cleared for marketing by the FDA.

OCL 500 is a patented, first in class embolization agent that represents a paradigm shift in treatment compared to currently marketed embolic agents.  OCL 500 is a microspherical agent in development for the treatment of highly vascularised tumours, including hepatocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids.  OCL 500 microspheres rapidly form a tight, efficient, site-specific and platelet-rich clot that cuts off the blood supply to tumours.  The OCL 500 microspheres then completely biodegrade over time, allowing the treated blood vessels to re-open and restore normal blood flow.  This is important because it enables multiple embolization treatments of unresectable hypervascularized tumours, such as those associated with liver and kidney cancer, through the same vascular pathway.  

Mike Stewart, CEO of IMBio, stated, “No other embolization agent on the market today offers the advantages that OCL 500 microspheres offer. We believe that OCL 500 has the potential to broadly expand the number of embolization treatments conducted each year, and we are delighted to bring this very exciting product to the U.S. market. We plan to launch OCL 500 with a commercialization partner in the latter half of this year.”

About IMBio

IMBio is a privately held Canadian biotechnology company focused on developing medical device products for use in the area of embolotherapy. Lead product, OCL 500 microspheres for the treatment of unresectable/inoperable hypervascularized tumours has received marketing clearance from the FDA in the U.S.  Other products in development include rapidly-dissolving, drug-eluting and/or radio-labelled microspheres as well as biodegradable coils and stents for use in aneurysms that are not conducive to treatment with microspheres.

About Embolotherapy

Embolotherapy works by cutting off blood flow to benign and malignant hypervascular tumours. The procedure is performed by injecting agents through a catheter into the blood vessels that feed the target tumour. By selectively blocking blood supply, the deprived tumour is either destroyed or devitalized, resulting in therapeutic benefit. Hypervascular tumours are characterized by having an excessive number of blood vessels. Embolotherapy is a minimally invasive treatment for hypervascular tumours such as liver and kidney cancers as well as uterine fibroids. According to the National Cancer Institute, there are approximately 25,000 Americans with liver and intrahepatic bile duct cancer, and approximately 266,000 with kidney and renal pelvic cancer. Across the U.S., approximately 300,000 hysterectomies and 70,000 myomectomies are performed annually to treat uterine fibroids.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiary, may ultimately prove to be incorrect. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

FOR FURTHER INFORMATION PLEASE CONTACT:

IMBiotechnologies Ltd.

IMBiotechnologies Ltd.

Michael Stewart

Jean-Paul Laurin

President & CEO

Vice President, Business Development

(780) 945-6609

(905) 220-9933

mstewart@tbwifi.ca

jp.imbiotechnologies@bell.net

 

 

www.imbiotechnologies.com

NEWS RELEASE

March 19, 2010

IMBiotechnologies Receives Response to Submission to U.S. FDA for Marketing Authorization of Occlusin® 500 Artificial Embolization Device

 

EDMONTON, ALBERTA - IMBiotechnologies Ltd. ("IMBio"), a private biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received a response to its 510(k) Premarket Notification submission to the United States Food and Drug Administration (FDA) for its lead product, Occlusin® 500 Artificial Embolization Device (OCL 500). IMBio filed the 510(k) submission in December 2009.

The FDA has responded with several questions for additional information that would further establish the safety and efficacy of OCL 500. IMBio continues to work closely with the FDA to ensure that all questions are fully addressed.

As expected, the FDA is treating the OCL 500 submission as a 510(k) rather than a PMA submission.

Michael Stewart, CEO of IMBio, stated, “We look forward to providing everything necessary to satisfy the information requests of the FDA and we remain committed to seeing OCL 500 become the first biodegradable embolic approved for hypervascular tumours. In the meantime, we are continuing our efforts to establish a strategic alliance for marketing, sales and distribution of OCL 500 worldwide.”

Hypervascular tumours are characterized by having an excessive number of blood vessels. Embolotherapy is a minimally invasive treatment for hypervascular tumours such as liver and kidney cancers as well as uterine fibroids. According to the National Cancer Institute, there are approximately 25,000 Americans with liver and intrahepatic bile duct cancer, and approximately 266,000 with kidney and renal pelvic cancer. Across the U.S., approximately 300,000 hysterectomies and 70,000 myomectomies are performed annually to treat uterine fibroids. Therefore, “the marketing opportunity represented by OCL 500 is very large, and we are very optimistic about the future potential of this product in the American marketplace”, added Stewart.

About IMBio

IMBio is a privately held Canadian biotechnology company focused on developing medical device products for use in the area of embolotherapy. Embolotherapy works by cutting off blood flow to benign and malignant hypervascular tumours. The procedure is performed by injecting agents through a catheter into the blood vessels that feed the target tumour. By selectively blocking blood supply, the deprived tumour is either destroyed or devitalized, resulting in therapeutic benefit. IMBio's Lead Product Candidate, OCL 500, is a "first in class" biodegradable embolic microspherical agent in development for the treatment of highly vascularised tumours, including hepatocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids. OCL 500 is on target for commercialization in the second half of 2010.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiary, may ultimately prove to be incorrect. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

FOR FURTHER INFORMATION PLEASE CONTACT:

 

 

IMBiotechnologies Ltd.

IMBiotechnologies Ltd.

Michael Stewart

Jean-Paul Laurin

President & CEO

Vice President, Business Development

                            (780) 945-6609         (780) 945-6609                       (780) 945-6609         (780) 945-6609

                            (905) 220-9933         (905) 220-9933                       (905) 220-9933         (905) 220-9933

mstewart@tbwifi.ca

jp.imbiotechnologies@bell.net

 

 

 

www.imbiotechnologies.com

 

 

 

NEWS RELEASE

DECEMBER 11, 2009

 

IMBiotechnologies Announces Submission to U.S. FDA for Marketing Authorization of Occlusin® 500 Artificial Embolization Device

 

EDMONTON, ALBERTA - IMBiotechnologies Ltd. ("IMBio"), a private biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced the submission to the United States Food and Drug Administration (FDA) of a 510(k) Premarket Notification for its lead product, Occlusin® 500 Artificial Embolization Device (OCL 500). This 510(k) filing specifies treatment of hypervascular tumours, and is subject to a 90 day review period, which is FDA standard for a medical device product. The Company plans to file a supplemental 510(k) specifying treatment of uterine fibroids following the completion of a pivotal clinical trial in patients with this disorder.

 

Michael Stewart, CEO of IMBio, stated, “This is a tremendous achievement for IMBio, demonstrating the strong commitment and dedication of our team, and our ability to meet the objectives we have set for ourselves. If a positive review is received from the FDA, OCL 500 will become the first biodegradable embolic approved for treatment of hypervascular tumours. We will now concentrate our efforts on establishing a strategic alliance for marketing, sales and distribution of OCL 500.”

 

Hypervascular tumours are characterized by having an excessive number of blood vessels. Embolotherapy is a minimally invasive treatment for hypervascular tumours such as liver and kidney cancers as well as uterine fibroids. According to the National Cancer Institute, there are approximately 25,000 Americans with liver and intrahepatic bile duct cancer, and approximately 266,000 with kidney and renal pelvic cancer. Across the U.S., approximately 300,000 hysterectomies and 70,000 myomectomies are performed annually to treat uterine fibroids. Therefore, “the marketing opportunity represented by OCL 500 is very large, and we are very optimistic about the future potential of this product in the American marketplace”, added Stewart.

 

About IMBio

 

IMBio is a privately held Canadian biotechnology company focused on developing medical device products for use in the area of embolotherapy. Embolotherapy works by cutting off blood flow to benign and malignant hypervascular tumours. The procedure is performed by injecting agents through a catheter into the blood vessels that feed the target tumour. By selectively blocking blood supply, the deprived tumour is either destroyed or devitalized, resulting in therapeutic benefit. IMBio's Lead Product Candidate, OCL 500, is a "first in class" biodegradable embolic microspherical agent in development for the treatment of highly vascularised tumours, including hepatocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids. OCL 500 is on target for commercialization in the second half of 2010.

 

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiary, may ultimately prove to be incorrect. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

 

 

FOR FURTHER INFORMATION PLEASE CONTACT: IMBiotechnologies Ltd.

 

 

IMBiotechnologies Ltd.

Michael Stewart

Jean-Paul Laurin

President & CEO

Vice President, Business Development

                            (780) 945-6609         (780) 945-6609                       (780) 945-6609         (780) 945-6609

                            (905) 220-9933         (905) 220-9933                       (905) 220-9933         (905) 220-9933

mstewart@tbwifi.ca

jp.imbiotechnologies@bell.net

 

 

 

NOVEMBER 18, 2009

IMBiotechnologies Announces Douglas Deeth joins Board of Directors

EDMONTON, ALBERTA - IMBiotechnologies Ltd. ("IMBio"), a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced the addition of Mr. Douglas Deeth to its board of Directors.

Mr. Deeth is a founding member of the Deeth Williams Wall legal firm in Toronto. Over the past 25 years, he has become one of Canada’s premier lawyers in the areas of intellectual property and technology law, concentrating on licensing and litigation matters. He regularly advises and counsels clients on the clearance, protection and enforcement of all forms of technology and intellectual property rights, and has particular expertise in chemical and pharmaceutical products and processes. Mr. Deeth is a former President of the Intellectual Property Section of the Canadian Bar Association and is the Past President of Fédération Internationale des Conseils en Propriété Industrielle Canada. He is an active member of several other Canadian, American and international organizations including the Intellectual Property Institute of Canada and the American Intellectual Property Law Association.

Michael Stewart, CEO of IMBio, stated, “With Doug joining our Board, we now have a very experienced intellectual property and licensing professional to advise us with our continued development of the Occlusin® technology and partnering our lead product, Occlusin® 500 Artificial Embolization Device (OCL 500). We are pleased to welcome Doug to our team and look forward to working with him to partner and bring OCL 500 to market.”

About IMBio

IMBio is a privately held Canadian biotechnology company focused on developing medical device products for use in the area of embolotherapy. Embolotherapy works by cutting off blood flow to target tissues, usually benign and malignant tumours. The procedure is performed by injecting agents through a catheter and into the blood vessels that feed the target tumour. By selectively blocking blood supply, the deprived tumour is either destroyed or devitalized, resulting in therapeutic benefit. IMBio's Lead Product Candidate, OCL 500, is a "first in class" biodegradable embolic agent for the treatment of malignant and non-malignant vascularised tumors, including hepatocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids. OCL 500 is on target from commercialization in the second half of 2010.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiary, may ultimately prove to be incorrect. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

FOR FURTHER INFORMATION PLEASE CONTACT:

 

 

IMBiotechnologies Ltd.

 

Michael Stewart

 

Chief Executive Officer

 

                                          (780) 945-6609         (780) 945-6609                       (780) 945-6609         (780) 945-6609                                      (780) 945-6609         (780) 945-6609                       (780) 945-6609         (780) 945-6609  

                                          (780) 945-6609         (780) 945-6609                       (780) 945-6609         (780) 945-6609                                      (780) 945-6609         (780) 945-6609                       (780) 945-6609         (780) 945-6609

 

(780) 987-0941 (fax)

 

mstewart@tbwifi.ca

 

www.imbiotechnologies.com

 

 

September 1, 2009

 

IMBiotechnologies Announces John Pinsent joins Board of Directors

EDMONTON, ALBERTA - IMBiotechnologies Ltd. ("IMBio"), a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced the addition of Mr. John Pinsent to its board of Directors.

Mr. Pinsent is a founding partner of St. Arnaud Pinsent Steman Chartered Accountants (“SPS”) following a distinguished ten-year career with Ernst and Young LLP.  At SPS, John specializes in providing accounting, audit, tax and business advisory services for owner-managed businesses.  John has a particular passion for assisting early stage technology and biotechnology companies and has been an active angel investor and mentor to organizations in this space.  During his many years in public practice, John has built a strong network of contacts from various industries and he regularly uses this support network to assist his clients and investee companies build value for the their enterprises.

Michael Stewart, CEO of IMBio, stated, “We are very pleased to have John join our team. John’s experience with both private and public sector companies will be a tremendous asset as our company continues to grow and we proceed to partnering and commercializing our lead product candidate, Occlusin® 500 Artificial Embolization Device (OCL 500).”

About IMBio

IMBio is a privately held Canadian biotechnology company focused on developing medical device products for use in the area of embolotherapy. Embolotherapy works by cutting off blood flow to target tissues, usually benign and malignant tumours. The procedure is performed by injecting agents through a catheter and into the blood vessels that feed the target tumour. By selectively blocking blood supply, the deprived tumour is either destroyed or devitalized, resulting in therapeutic benefit. IMBio's Lead Product Candidate, OCL 500, is a "first in class" biodegradable embolic agent for the treatment of malignant and non-malignant vascularised tumors, including hepatocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids. OCL 500 is on target from commercialization in the second half of 2010.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiary, may ultimately prove to be incorrect. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

FOR FURTHER INFORMATION PLEASE CONTACT:

 

 

IMBiotechnologies Ltd.

 

Michael Stewart

 

Chief Executive Officer

 

                                          (780) 945-6609         (780) 945-6609                       (780) 945-6609         (780) 945-6609                                      (780) 945-6609         (780) 945-6609                       (780) 945-6609         (780) 945-6609  

                                          (780) 945-6609         (780) 945-6609                       (780) 945-6609         (780) 945-6609                                      (780) 945-6609         (780) 945-6609                       (780) 945-6609         (780) 945-6609

 

(780) 987-0941 (fax)

 

mstewart@tbwifi.ca

 

www.imbiotechnologies.com

 

 

 

September 8, 2009

 

IMBiotechnologies Announces Jean-Paul Laurin Joins Executive Team

 

EDMONTON, AB --- September 8, 2009 - IMBiotechnologies Ltd. ("IMBio"), a private biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced the addition of Jean-Paul Laurin to it’s Executive Team as Vice-President, Business Development.

Mr. Laurin brings to IMBio 15 years experience in the pharmaceutical, biotechnology and medical device industries, 10 of which have been spent in Business Development roles. His experience includes national and international product licensing, development and manufacturing agreements, as well as mergers, acquisitions and initial public offerings. Mr. Laurin has a B.Comm and M.Sc. degree from Concordia University in Montreal Canada.

Michael Stewart, President & CEO of IMBio, stated, “With the addition of Jean-Paul to the Executive Team, we now have in place all of the key elements required to secure sufficient financing to commercialize IMBio’s lead product, Occlusin™ 500 Artificial Embolization Device (OCL 500 AED). We are very happy to welcome Jean-Paul to our team and look forward to working together to achieve this important milestone for our company.”

About IMBio

IMBio is a privately held Canadian biotechnology company focused on developing medical device products for use in the area of embolotherapy. Embolotherapy works by cutting off blood flow to target tissues, usually benign and malignant growths (tumours). The procedure is performed by injecting agents through a catheter and into the blood vessels that feed the target tumour. By selectively blocking blood supply, the deprived tumour is either destroyed or devitalized, resulting in therapeutic benefit. IMBio's Lead Product Candidate, OCL 500 AED, is a "first in class" biodegradable embolic agent for the treatment of malignant and non-malignant vascularised tumors, including hepatocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiary, may ultimately prove to be incorrect. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

 

 

AUGUST 21, 2009

 

IMBiotechnologies Announces Dr. Ruth Collins-Nakai joins Board of Directors

 

EDMONTON, ALBERTA - IMBiotechnologies Ltd. ("IMBio"), a private biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced the addition of Dr. Ruth Collins-Nakai to the Company’s Board of Directors.

Dr. Collins-Nakai is a former academic cardiologist whose research and teaching has spanned 30 years at the University of Alberta. Dr. Collins-Nakai has an MBA from the University of Alberta and has broadly consulted in the areas of health, biotechnology and education. Dr. Collins-Nakai is a former Associate Dean Faculty of Medicine, University of Alberta, founding member of the Canadian Institute of Health Research’s Governing Council (CIHR), Past Chair of the Board of Governors and member of the Executive and Board of Trustees of the American College of Cardiology, Past President of both the Canadian Cardiovascular Society and InterAmerica Society of Cardiology, Past President of both the Alberta Medical Association, and Canadian Medical Association.

Michael Stewart, CEO of IMBio, stated, “We are very pleased to have Dr. Collins-Nakai join our team. Her broad medical and policy background, business experience and international recognition as a Key Opinion Leader are all tremendous assets for IMBio. The fact that she has considerable experience in interventional procedures is a significant benefit.  We are looking forward to working with Dr. Collins-Nakai to build IMBio into a world-class biotechnology company.”

About IMBio

IMBio is a privately held Canadian biotechnology company focused on developing medical device products for use in the area of embolotherapy. Embolotherapy works by cutting off blood flow to target tissues, usually benign and malignant growths (tumours). The procedure is performed by injecting agents through a catheter and into the blood vessels that feed the target tumour. By selectively blocking blood supply, the deprived tumour is either destroyed or devitalized, resulting in therapeutic benefit. IMBio's Lead Product Candidate, Occlusin® 500 Artificial Embolization Device (OCL 500 AED), is a "first in class" biodegradable embolic agent for the treatment of malignant and non-malignant vascularised tumors, including hepatocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiary, may ultimately prove to be incorrect. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

 

August 13, 2009

 

IMBiotechnologies Ltd completes purchase of ‘Tumor Starvation Technology’ from Paladin Labs Inc.

Edmonton, AB --- August 13, 2009 – IMBiotechnologies Ltd (“IMBio”) announced today that the Company has completed purchase of all assets related to the Occlusin® tumor starvation technology from Paladin Labs Inc (“Paladin”).  In addition to the cash payment provided to purchase the technology, Paladin will receive a one time milestone payment on first sale of product and a royalty with a capped payment.  IMBio will focus its efforts on obtaining regulatory approval for its lead product candidate, Occlusin® 500 Artificial Embolization Device (“OCL 500 AED”), which is a medical device.

“All pre-clinical testing of the OCL 500 AED medical device is complete and we are in the process of assembling the pre-market notification (510(k)) submission to the FDA,” commented Michael Stewart, President & CEO of IMBio.  “The OCL 500 AED embolic agent cuts off the blood supply to tumors and demonstrates equivalent safety and effectiveness in comparison to currently approved embolic agents.  One of the significant advantages of OCL 500 AED is that it is biodegradable and is slowly broken down by the body until it ultimately disappears.  Competitor’s products are permanent implants and stay in the body for the life of the patient.”

OCL 500 AED is designed for the treatment of malignant and non-malignant vascularised tumors.  Examples of vascularised tumors include heptocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids.  Over 2 million women in the USA alone suffer from debilitating effects of uterine fibroids.

About Paladin Labs Inc.

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Company's web site at www.paladinlabs.com.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company may ultimately prove to be incorrect. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

 

For more information, please contact:

 

Michael Stewart

Chief Executive Officer

IMBiotechnologies Ltd

Tel:                                            (780) 945-6609         (780) 945-6609                       (780) 945-6609         (780) 945-6609                                      (780) 945-6609         (780) 945-6609                       (780) 945-6609         (780) 945-6609                                                    (780) 945-6609         (780) 945-6609                       (780) 945-6609         (780) 945-6609                                      (780) 945-6609         (780) 945-6609                       (780) 945-6609         (780) 945-6609

Fax: (780) 987-0941

mstewart@tbwifi.ca

Samira Sakhia

Chief Financial Officer

Paladin Labs Inc.

                                          514-669-5367         514-669-5367                       514-669-5367         514-669-5367                                      514-669-5367         514-669-5367                       514-669-5367         514-669-5367

514-344-4675 (FAX)

info@paladin-labs.com